Royalty Pharma Research and Development Expenses 2019-2024 | RPRX

Royalty Pharma research and development expenses for the twelve months ending September 30, 2024 were $2M, a 98.04% decline year-over-year.

  • Royalty Pharma annual research and development expenses for 2023 were $0.052B, a 70.64% decline from 2022.
  • Royalty Pharma annual research and development expenses for 2022 were $0.177B, a 11.48% decline from 2021.
  • Royalty Pharma annual research and development expenses for 2021 were $0.2B, a 661.09% increase from 2020.

Royalty Pharma Research and Development Expenses 2019-2024 | RPRX

  • Royalty Pharma annual research and development expenses for 2023 were $0.052B, a 70.64% decline from 2022.
  • Royalty Pharma annual research and development expenses for 2022 were $0.177B, a 11.48% decline from 2021.
  • Royalty Pharma annual research and development expenses for 2021 were $0.2B, a 661.09% increase from 2020.
Related Stocks
Company NameMarket
Cap
American Express (AXP)$202.6B
Blackstone (BX)$128.1B
Moody's (MCO)$86.5B
Orix Corp Ads (IX)$26.4B
Brookfield Asset Management (BAM)$25.1B
Synchrony Financial (SYF)$24.8B
Grupo Financiero Banorte SAB De CV (GBOOY)$20.4B
Equitable Holdings (EQH)$14.8B
Jefferies Financial Group (JEF)$14.7B
SoFi Technologies (SOFI)$13.9B
Houlihan Lokey (HLI)$12.9B
Daiwa Securities Group (DSEEY)$9.7B
XP (XP)$9.4B
Globe Life (GL)$9.2B
Brookfield Wealth Solutions (BNT)$8.3B
SouthState (SSB)$8.3B
Jackson Financial (JXN)$8.1B
StepStone Group (STEP)$7.5B
Upstart Holdings (UPST)$7.3B
Freedom Holding (FRHC)$6.6B
Lazard (LAZ)$6.6B
Blue Owl Capital (OBDC)$5.8B
Rithm Capital (RITM)$5.6B
Virtu Financial (VIRT)$5.3B
Core Scientific (CORZ)$4.7B
AXOS FINANCIAL, INC (AX)$4.6B
Euronet Worldwide (EEFT)$4.5B
PJT Partners (PJT)$3.8B
Community Financial System (CBU)$3.6B
Cleanspark (CLSK)$3.4B